Section Arrow
ZVSA.NASDAQ
- ZyVersa Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2024/05/04 22:06 EDT
Last
 5.45
-0.29 (-5.05%)
Day High 
Prev. Close
5.74 
1-M High
8.046 
Volume 
374.83K 
Bid
5.4
Ask
5.48
Day Low
5.2501 
Open
5.58 
1-M Low
4.4401 
Market Cap 
4.36M 
Currency USD 
P/E -- 
%Yield
10-SMA 5.64 
20-SMA 6.23 
50-SMA 7.56 
52-W High 220.85 
52-W Low 4.4401 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1,089.70/-46.10
Enterprise Value
4.36M
Balance Sheet
Book Value Per Share
14.58
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
JAGXJaguar Health0.318+0.0248+8.46%-- 
VAXXVaxxinity0.1411+0.0369+35.41%-- 
DNAGinkgo Bioworks Holdings0.955+0.0939+10.90%-- 
ARDXArdelyx8.72+1.93+28.42%-- 
IBRXImmunityBio9.15+0.18+2.01%-- 
Quotes are at least 15-min delayed:2024/05/04 22:06 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.